Plain-English translation of NCT01371630 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of a newer targeted drug called with lower-dose chemotherapy for people with acute lymphoblastic leukemia (ALL) — a serious blood cancer. The trial focuses on older patients (age 60+) and younger patients who are too frail for standard intensive chemotherapy. Researchers want to find the right dose of this medication and see whether this combination is effective and safe for these patient groups.
Older and medically fragile patients with ALL often cannot tolerate the strongest chemotherapy treatments available. This trial exists to find a gentler combination that still fights the cancer effectively, combining a targeted medication that homes in on cancer cells with lower-intensity chemotherapy to reduce side effects.
You likely qualify if…
You likely don't qualify if…
You would receive treatment in cycles lasting 3–4 weeks each, alternating between two types of chemotherapy regimens. In some cycles, you would receive the newer targeted medication () by intravenous infusion along with other chemotherapy drugs and supportive medications. Chemotherapy is given intravenously, and some medications are delivered directly into the spinal fluid. You would have regular blood tests and monitoring visits to check how well the treatment is working and watch for side effects. The trial includes two phases: Phase 1 finds the safest dose, and Phase 2 tests how well this combination works.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
United States